Kevin C Maki Selected Research

Hypertriglyceridemia

1/2022	Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
1/2022	A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
1/2020	Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
7/2018	Omega-3 Fatty Acid Supplementation and Cardiovascular Disease Risk: Glass Half Full or Time to Nail the Coffin Shut?
11/2017	Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia.
3/2017	Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
3/2017	Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid TechnologiesTM (ALT®)-based formulation.
3/2017	A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid TechnologiesTM (ALT®) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza®.
1/2017	Replacement of Refined Starches and Added Sugars with Egg Protein and Unsaturated Fats Increases Insulin Sensitivity and Lowers Triglycerides in Overweight or Obese Adults with Elevated Triglycerides.
1/2017	Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevin C Maki Research Topics

Disease

30	Cardiovascular Diseases (Cardiovascular Disease) 11/2021 - 08/2005
26	Hypertriglyceridemia 01/2022 - 11/2005
20	Dyslipidemias (Dyslipidemia) 01/2022 - 01/2004
17	Insulin Resistance 05/2022 - 05/2009
16	Type 2 Diabetes Mellitus (MODY) 02/2022 - 12/2007
16	Overweight 01/2020 - 05/2007
12	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 01/2004
11	Coronary Disease (Coronary Heart Disease) 01/2020 - 01/2004
10	Hypercholesterolemia 10/2018 - 03/2003
9	Body Weight (Weight, Body) 01/2022 - 12/2002
7	Diabetes Mellitus 02/2022 - 01/2006
7	Weight Loss (Weight Reduction) 01/2022 - 12/2002
6	Atherosclerosis 01/2018 - 10/2008
5	Prediabetic State (Prediabetes) 02/2022 - 05/2018
5	Hypertension (High Blood Pressure) 01/2022 - 01/2004
4	Inflammation (Inflammations) 11/2021 - 05/2014
4	Obesity 09/2011 - 12/2002
3	Stroke (Strokes) 01/2020 - 05/2014
3	Myocardial Infarction 01/2020 - 05/2014
2	Death (Near-Death Experience) 07/2018 - 09/2017
2	Myalgia 01/2018 - 01/2014
2	Chronic Disease (Chronic Diseases) 11/2017 - 07/2012
2	Coronary Artery Disease (Coronary Atherosclerosis) 06/2014 - 11/2005
2	Pancreatitis 09/2012 - 09/2009
1	Noncommunicable Diseases 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Unstable Angina 01/2020
1	Heart Diseases (Heart Disease) 11/2018

Drug/Important Bio-Agent (IBA)

38	LipidsIBA 01/2022 - 03/2003
28	Triglycerides (Triacylglycerol)IBA 01/2022 - 12/2002
26	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 07/2007
22	Lipoproteins (Lipoprotein)IBA 01/2022 - 07/2007
17	LDL CholesterolIBA 01/2022 - 08/2005
16	CholesterolIBA 01/2020 - 01/2004
15	Glucose (Dextrose)FDA LinkGeneric 05/2022 - 05/2007
14	CarbohydratesIBA 02/2022 - 10/2008
14	HDL CholesterolIBA 01/2022 - 11/2005
13	EstersIBA 01/2022 - 07/2007
13	oxidized low density lipoproteinIBA 11/2021 - 06/2006
10	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2020 - 09/2009
8	Insulin (Novolin)FDA Link 05/2022 - 05/2007
8	Pharmaceutical PreparationsIBA 01/2022 - 01/2004
8	Fatty Acids (Saturated Fatty Acids)IBA 11/2021 - 12/2002
7	Eicosapentaenoic AcidIBA 01/2022 - 12/2011
6	Docosahexaenoic AcidsIBA 01/2022 - 09/2009
6	Simvastatin (Zocor)FDA LinkGeneric 05/2010 - 07/2007
5	Nonesterified Fatty Acids (NEFA)IBA 01/2022 - 09/2007
5	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020 - 06/2006
5	lipoprotein cholesterolIBA 01/2019 - 01/2012
4	AcidsIBA 01/2022 - 08/2008
4	CalciumIBA 01/2021 - 11/2012
4	ApolipoproteinsIBA 01/2020 - 10/2009
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 05/2011
4	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2018 - 12/2011
4	Corn Oil (Oil, Corn)IBA 10/2018 - 09/2011
4	Fibric Acids (Fibrates)IBA 08/2017 - 01/2004
4	Olive OilIBA 01/2015 - 09/2009
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 05/2022 - 12/2007
3	HDL LipoproteinsIBA 11/2021 - 11/2005
3	Carboxylic AcidsIBA 01/2020 - 09/2014
3	C-Reactive ProteinIBA 01/2020 - 08/2011
3	Proteins (Proteins, Gene)FDA Link 05/2018 - 12/2017
3	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 09/2015 - 10/2009
3	Fenofibrate (CiL)FDA LinkGeneric 06/2014 - 06/2006
3	Atorvastatin (Lipitor)FDA Link 06/2014 - 11/2011
3	Phytosterols (Plant Sterols)IBA 02/2014 - 03/2003
3	Vitamin D FDA LinkGeneric 11/2012 - 06/2011
3	25-hydroxyvitamin DIBA 10/2012 - 08/2009
3	hydroxide ionIBA 10/2012 - 08/2009
3	Indicators and Reagents (Reagents)IBA 01/2012 - 05/2009
3	Adenosine Triphosphate (ATP)IBA 01/2006 - 06/2004
2	Glucagon-Like Peptide 1 (GLP 1)IBA 05/2022 - 10/2008
2	eicosapentaenoic acid ethyl esterIBA 01/2022 - 01/2020
2	Apolipoprotein C-IIIIBA 11/2021 - 11/2011
2	Dietary CholesterolIBA 01/2020 - 01/2019
2	Dietary Fats (Dietary Fat)IBA 11/2018 - 03/2017
2	MAT9001IBA 11/2017 - 01/2017
2	Niacin (Nicotinic Acid)FDA LinkGeneric 08/2017 - 09/2012
2	SugarsIBA 01/2017 - 03/2015
2	VLDL CholesterolIBA 01/2017 - 11/2011
2	Dietary Fiber FDA Link 02/2015 - 04/2014
2	fenofibric acid FDA Link 06/2014 - 08/2012
2	Ezetimibe (Zetia)FDA Link 09/2013 - 10/2008
2	Menhaden oilIBA 01/2011 - 09/2009
2	Hypromellose DerivativesIBA 02/2009 - 02/2008
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022
1	ElementsIBA 01/2022
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2020
1	Apolipoproteins B (ApoB)IBA 01/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019
1	Coconut OilIBA 10/2018
1	AlbuminsIBA 01/2018
1	CreatinineIBA 01/2018
1	Lipoprotein(a)IBA 01/2018

Therapy/Procedure

29	Therapeutics 01/2020 - 01/2004
4	Drug Therapy (Chemotherapy) 03/2016 - 09/2014
3	Glycemic Control 12/2021 - 09/2019
2	Ketogenic Diet 01/2022 - 09/2019
1	Carbohydrate Loading Diet 02/2022
1	Mediterranean Diet 01/2019